AF
AIMT

Advisornet Financial’s Aimmune Therapeutics AIMT Stock Holding History

Advisornet Financial’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-406
Closed -$7K – 1956
2020
Q2 		$7K Hold
406
– – ﹤0.01% 1405
2020
Q1 		$6K Hold
406
– – ﹤0.01% 1415
2019
Q4 		$14K Buy
+406
New +$11.3K ﹤0.01% 1303

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Advisornet Financial's AIMT Position: Q3 2020 in Review

Advisornet Financial sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 406 shares — an estimated $7K sold.

Advisornet Financial first reported a position in AIMT in Q4 2019 and held it in 3 quarters. The position peaked at $14K in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Advisornet Financial reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Advisornet Financial sold 406 Aimmune Therapeutics shares in Q3 2020, an estimated $7K.
  • Advisornet Financial first reported a position in Aimmune Therapeutics in Q4 2019 and held it in 3 quarters.
  • Advisornet Financial's Aimmune Therapeutics position peaked at $14K in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Advisornet Financial's 13F filing for Q3 2020, filed 6 Nov 2020.